Status and phase
Conditions
Treatments
About
Opioid-induced bowel dysfunction is a frequent condition during opioid therapy for chronic pain. Indeed, up to 90% of people on opioid treated patients experience constipation. Standard laxative treatment is often ineffective in opioid-induced constipation, but peripheral acting mu-receptor antagonists (PAMORAs) have the potential to block the effects of opioids in the gastrointestinal tract while preserving the central analgesic effect. In this study, we will investigated the effects of Naldemedine in preventing the development of opioid-induced bowel dysfunction and constipation during treatment with tramadol
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Known hypersensitivity or allergy towards the used pharmaceutical compounds or pharmaceutical compounds similar to those used in the study.
History of substance abuse (alcohol, tetrahydrocannabinol, benzodiazepine, central stimulants and/or opioids, urine drug test will be performed prior to treatment start).
Primary purpose
Allocation
Interventional model
Masking
20 participants in 2 patient groups, including a placebo group
Loading...
Central trial contact
Asbjørn Mohr Drewes
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal